Characterization of Susceptibility Variants of Influenza Virus Grown in the Presence of T-705

被引:22
|
作者
Daikoku, Tohru [1 ]
Yoshida, Yoshihiro [1 ]
Okuda, Tomoko [1 ]
Shiraki, Kimiyasu [1 ]
机构
[1] Toyama Univ, Dept Virol, Toyama 9300194, Japan
基金
日本学术振兴会;
关键词
influenza virus; T-705; favipiravir; RNA-POLYMERASE; IN-VITRO; SUBUNIT; ACYCLOVIR; FAVIPIRAVIR; RESISTANCE; PB2;
D O I
10.1254/jphs.14156SC
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
T-705 (favipiravir) is a potent inhibitor of RNA polymerases of influenza viruses. Susceptibility variants were isolated during passages in the presence of T-705. Nine variants with 0.4 to 2.1 times the 50% inhibitory concentration for plaque formation of the parent A/PR/8/34 (H1N1) strain had amino acid variations in the PB1, PB2, and PA genes of the RNA polymerase complex. However, the variation patterns in the RNA polymerase complex indicated that T-705 does not work as a mutagen, and resistant mutants were not isolated, possibly because a mutation leading to resistance would be lethal to the RNA polymerase function.
引用
收藏
页码:281 / 284
页数:4
相关论文
共 50 条
  • [1] Mechanism of action of T-705 against influenza virus
    Furuta, Y
    Takahashi, K
    Kuno-Maekawa, M
    Sangawa, H
    Uehara, S
    Kozaki, K
    Nomura, N
    Egawa, H
    Shiraki, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) : 981 - 986
  • [2] T-705 (Favipiravir) suppresses tumor necrosis factor a production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug
    Tanaka, T.
    Kamiyama, T.
    Daikoku, T.
    Takahashi, K.
    Nomura, N.
    Kurokawa, M.
    Shiraki, K.
    ACTA VIROLOGICA, 2017, 61 (01) : 48 - 55
  • [3] Effects of the Combination of Favipiravir (T-705) and Oseltamivir on Influenza A Virus Infections in Mice
    Smee, Donald F.
    Hurst, Brett L.
    Wong, Min-Hui
    Bailey, Kevin W.
    Tarbet, E. Bart
    Morrey, John D.
    Furuta, Yousuke
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) : 126 - 133
  • [4] In vitro and in vivo activities of anti-influenza virus compound T-705
    Furuta, Y
    Takahashi, K
    Fukuda, Y
    Kuno, M
    Kamiyama, T
    Kozaki, K
    Nomura, N
    Egawa, H
    Minami, S
    Watanabe, Y
    Narita, H
    Shiraki, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) : 977 - 981
  • [5] In Vivo Pharmacodynamic Characterization of T-705 in an Experimental Influenza Infection Model in Mice
    Takahashi, K.
    Kadota, T.
    Tanaka, T.
    Komeno, T.
    Hayakawa, H.
    Mitsuyama, J.
    Furuta, Y.
    Shiraki, K.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : E170 - E171
  • [6] Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase
    Sangawa, Hidehiro
    Komeno, Takashi
    Nishikawa, Hiroshi
    Yoshida, Atsushi
    Takahashi, Kazumi
    Nomura, Nobuhiko
    Furuta, Yousuke
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (11) : 5202 - 5208
  • [7] Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis
    Vanderlinden, Evelien
    Vrancken, Bram
    Van Houdt, Jeroen
    Rajwanshi, Vivek K.
    Gillemot, Sarah
    Andrei, Graciela
    Lemey, Philippe
    Naesens, Lieve
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (11) : 6679 - 6691
  • [8] T-705, A Novel Anti-Influenza Virus Compound - the Safety, Tolerability and Pharmacokinetics in Human
    Kobayashi, O.
    Noto, M.
    Sakurai, T.
    Iwamoto, A.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : E299 - E299
  • [9] Anti-influenza Virus Activity of Methylthio-Formycin Distinct From That of T-705
    Takizawa, Naoki
    Takada, Hisashi
    Umekita, Maya
    Igarashi, Masayuki
    Takahashi, Yoshiaki
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [10] Combination of Neuraminidase Inhibitors with T-705 for Treating Influenza Virus Infections in Cell Culture and in Mice
    Smee, Donald
    Wong, Min-Hui
    Bailey, Kevin
    Morrey, John
    Maekawa, Masako
    Takahashi, Kazumi
    Furuta, Yousuke
    ANTIVIRAL RESEARCH, 2009, 82 (02) : A37 - A37